Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
about
Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDSThe role of lopinavir/ritonavir (Kaletra) in the management of HIV infected adults.Long-term treatment of patients with HIV-1: the role of atazanavirInitial therapy for human immunodeficiency virus: broadening the options.Actual medication pill burden and dosing frequency in HIV-infected patients with undetectable viral loads.Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.Atazanavir for the treatment of human immunodeficiency virus infection.Atazanavir: the advent of a new generation of more convenient protease inhibitors.Review of atazanavir: a novel HIV protease inhibitor.Strategies for management and treatment of dyslipidemia in HIV/AIDS.Antiretroviral treatment regimen outcomes among HIV-infected prisoners.Atazanavir: simplicity and convenience in different scenarios.Role of atazanavir in the treatment of HIV infectionHIV protease inhibitors: recent clinical trials and recommendations on use.Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities.Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.Predictors of virological response to atazanavir in protease inhibitor-experienced patients.[Metabolic alterations in HIV-associated lipodystrophy syndrome].Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.Rash in an HIV-positive patient.A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients
P2860
Q24792952-C01E2BB0-3257-4C6A-9450-1FCADD78614DQ30343901-F23AD421-E9D2-4831-9AF2-AA8B47924EA5Q35557219-85B1C8DB-F173-4C3E-9787-569D7699D3A0Q35759609-B5007233-57DD-4643-884C-DFF03A7C0643Q35878022-A3D4EAC3-DA88-48CF-920D-E402DC352221Q35968731-CEED1575-F89A-48E0-A702-086473FA0061Q35976835-3F7D8B81-12F2-4ECB-8DB4-84A2CF467EE2Q36070100-E3A25BA5-7C2F-4A24-AB53-E12F56487E76Q36222006-30A26A0A-E606-496C-B243-AFE762DCC29BQ36336563-189FC5BC-FE01-4ADE-92AA-50433B8B8432Q36692794-6F8DE50C-68E8-4F37-8681-C0DD5A9E690CQ36765802-FE0AC99B-1797-4D0D-8960-7DED046250CDQ37230298-2B20B0B0-3D64-43F4-8D3C-A8D8A99F0543Q37519715-3DF70EAF-0E8C-4A3A-823D-811FD66830ADQ38069146-464EF19B-032F-409F-9420-EAF057D50EA9Q40903070-EC5A6148-78A3-4664-9464-3E2E767DFA7DQ43244207-09AEBC8E-0B8F-458D-A58E-6AAA985B7A2EQ45096975-21E8A816-BF29-4F57-BCB2-D7113BF54BBFQ45099760-40A3DAD1-062F-407E-9964-2E04BA4CAA3DQ46095764-B364B963-23FD-49DC-8415-4D1B97635EE6Q46127996-5DB35F7A-C03F-4991-B536-B47CDBA56152Q46789876-0DFA7F4B-7774-420A-B2A8-209F55CF5DC4Q57425194-0CC231F1-94C9-448A-9541-F63BAC8EBD52
P2860
Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Therapy with atazanavir plus s ...... mized comparative pilot trial.
@en
Therapy with atazanavir plus s ...... mized comparative pilot trial.
@nl
type
label
Therapy with atazanavir plus s ...... mized comparative pilot trial.
@en
Therapy with atazanavir plus s ...... mized comparative pilot trial.
@nl
prefLabel
Therapy with atazanavir plus s ...... mized comparative pilot trial.
@en
Therapy with atazanavir plus s ...... mized comparative pilot trial.
@nl
P2093
P1433
P1476
Therapy with atazanavir plus s ...... mized comparative pilot trial.
@en
P2093
Alexandra Thiry
Carlos Zala
Danilo Nunes
David W Haas
Hans Jaeger
Michael Sension
Peter Piliero
Protocol AI424-009 Study Group
Shannon Schrader
Steven Schnittman
P304
P356
10.1097/00002030-200306130-00008
P407
P577
2003-06-01T00:00:00Z